ClinicaliQ Trial Snapshot
- Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients — Active Not Recruiting • Phase III • NCT03814746.
- Crizanlizumab at two different doses tested against placebo to reduce pain crises in adolescents and adults with sickle cell disease.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit. Conditions: Sickle Cell Disease (SCD) Interventions: Crizanlizumab (SEG101), Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 255 participants